Logo

DRTS

Alpha Tau Medical Ltd.

DRTS

Alpha Tau Medical Ltd. • NASDAQ
$3.97 ▲ 5.59% (+0.21)
Market Cap $338.46 M
52w High $4.69
52w Low $2.30
Dividend Yield 0%
P/E -7.63
Volume 28.15K
Outstanding Shares 85.26M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $-48.642M ▼ $-11.686M ▼ 0% $-0.14 ▼ $-10.454M ▼
Q2-2025 $0 $9.648M ▲ $-10.114M ▼ 0% $-0.13 ▼ $-9.177M ▲
Q1-2025 $0 $9.308M ▼ $-8.691M ▲ 0% $-0.12 ▲ $-9.308M ▼
Q4-2024 $0 $10.274M ▲ $-9.476M ▼ 0% $-0.14 ▼ $-5.397M ▲
Q3-2024 $0 $8.29M $-6.924M 0% $-0.099 $-8.021M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $72.211M ▼ $104.694M ▼ $27.11M ▲ $77.584M ▼
Q2-2025 $79.699M ▲ $110.954M ▲ $24.331M ▼ $86.623M ▲
Q1-2025 $51.636M ▼ $80.928M ▼ $24.603M ▲ $56.325M ▼
Q4-2024 $59.6M ▼ $86.204M ▼ $23.538M ▲ $62.666M ▼
Q3-2024 $65.222M $90.727M $21.329M $69.398M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-11.686M ▼ $0 $0 $0 $-8.259M ▼ $0
Q2-2025 $-10.114M ▼ $0 $0 $0 $7.026M ▲ $0
Q1-2025 $-8.691M ▲ $0 $0 $0 $-8.748M ▼ $0
Q4-2024 $-9.476M ▼ $0 $0 $0 $8.251M ▲ $0
Q3-2024 $-6.924M $0 $0 $0 $2.85M $0

Five-Year Company Overview

Income Statement

Income Statement Alpha Tau is still a pure research and development story: it has essentially no product revenue yet and runs consistent, moderate losses. Expenses appear relatively well controlled and have not exploded over time, which suggests a lean cost structure. However, the company is clearly a long way from profitability and will likely remain loss‑making until it gains approvals and begins commercial sales. The main message from the income statement is that this is an early‑stage biotech with ongoing R&D and operating costs but no offsetting income stream yet.

Balance Sheet

Balance Sheet The balance sheet is small but has improved over the last few years. Total assets have crept upward, and equity has moved from negative to positive, which is a healthy sign. Debt is present but not large relative to the company’s size, so financial leverage does not look extreme. On the other hand, the absolute cash position appears limited, which constrains financial flexibility. Overall, the company has cleaned up its capital base but still operates with a modest financial cushion typical of a pre‑revenue biotech.

Cash Flow

Cash Flow Cash flows show a steady, ongoing cash burn from running the business and funding research, with only light spending on equipment and facilities so far. Operating cash outflows are consistent and not wildly volatile, which indicates predictable spending but no internal cash generation. Free cash flow is negative, meaning the company relies on external capital to fund its activities. This pattern is common for clinical‑stage biotech firms but highlights that future financing or partnerships will be important if revenue does not materialize soon.

Competitive Edge

Competitive Edge Alpha Tau’s competitive strength centers on its Alpha DaRT platform, which targets solid tumors using highly localized alpha radiation. It benefits from a sizable patent portfolio, a technically complex product that is not easy to copy, and special regulatory designations that can speed review in key indications. Early clinical data and expanding trials help build credibility and differentiate it from conventional radiation therapies and other oncology approaches. At the same time, it competes indirectly with entrenched cancer treatment modalities and large, well‑funded oncology players, so successful trial outcomes and smart commercialization will be critical to sustaining its edge.

Innovation and R&D

Innovation and R&D Innovation is the core of Alpha Tau’s value. The Alpha DaRT technology is a novel way to deliver powerful, short‑range radiation directly inside tumors, aiming to maximize tumor killing while sparing healthy tissue. The company is running trials across multiple hard‑to‑treat cancers, from skin and head‑and‑neck tumors to pancreatic and brain cancers, and is working toward regulatory approvals in several regions. It is also investing in manufacturing expansion to handle possible future demand. The upside of this R&D strategy is meaningful medical differentiation; the risk is that results, approvals, or scale‑up may fall short of expectations.

Summary

Alpha Tau Medical is a clinical‑stage oncology company focused on a single, highly innovative radiation platform, with no commercial revenue yet and a typical early‑stage financial profile: modest assets, improving but still thin equity, ongoing losses, and steady cash burn. Its main strengths lie in its differentiated technology, patent protection, regulatory momentum, and growing clinical evidence across several tumor types. Key uncertainties revolve around clinical trial outcomes, approval timelines, real‑world adoption versus existing cancer treatments, and the company’s ability to fund itself until commercialization. Observers will likely focus on trial readouts, regulatory decisions, manufacturing progress, and the company’s evolving cash position as the main drivers of its future trajectory.

NEWS

November 20, 2025 · 4:05 PM UTC

Alpha Tau Announces Third Quarter 2025 Financial Results and Provides Corporate Update

Read more

November 11, 2025 · 8:30 AM UTC

Alpha Tau to Participate at Jefferies Global Healthcare Conference in London

Read more

October 21, 2025 · 8:30 AM UTC

Alpha Tau Announces Receipt of Radioactive Material License for its New Hampshire Manufacturing Facility, Advancing Towards Commercial Readiness

Read more

September 2, 2025 · 8:30 AM UTC

Alpha Tau Successfully Treats First Patient in its U.S. Multi-Center Pancreatic Cancer Clinical Trial

Read more